Rhythm Pharmaceuticals Inc (RYTM)
59.03
-0.33
(-0.56%)
USD |
NASDAQ |
Nov 21, 16:00
61.00
+1.97
(+3.34%)
After-Hours: 05:39
Rhythm Pharmaceuticals Enterprise Value: 3.329B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 3.329B |
| November 20, 2024 | 3.350B |
| November 19, 2024 | 3.387B |
| November 18, 2024 | 3.297B |
| November 15, 2024 | 3.157B |
| November 14, 2024 | 3.375B |
| November 13, 2024 | 3.393B |
| November 12, 2024 | 3.639B |
| November 11, 2024 | 3.732B |
| November 08, 2024 | 3.840B |
| November 07, 2024 | 3.629B |
| November 06, 2024 | 3.552B |
| November 05, 2024 | 3.159B |
| November 04, 2024 | 2.958B |
| November 01, 2024 | 2.713B |
| October 31, 2024 | 2.634B |
| October 30, 2024 | 2.745B |
| October 29, 2024 | 2.745B |
| October 28, 2024 | 2.738B |
| October 25, 2024 | 2.684B |
| October 24, 2024 | 2.756B |
| October 23, 2024 | 2.713B |
| October 22, 2024 | 2.720B |
| October 21, 2024 | 2.785B |
| October 18, 2024 | 2.826B |
| Date | Value |
|---|---|
| October 17, 2024 | 2.837B |
| October 16, 2024 | 2.916B |
| October 15, 2024 | 2.799B |
| October 14, 2024 | 2.788B |
| October 11, 2024 | 2.762B |
| October 10, 2024 | 2.649B |
| October 09, 2024 | 2.633B |
| October 08, 2024 | 2.656B |
| October 07, 2024 | 2.601B |
| October 04, 2024 | 2.751B |
| October 03, 2024 | 2.686B |
| October 02, 2024 | 2.835B |
| October 01, 2024 | 2.882B |
| September 30, 2024 | 2.920B |
| September 27, 2024 | 2.960B |
| September 26, 2024 | 2.947B |
| September 25, 2024 | 3.015B |
| September 24, 2024 | 2.954B |
| September 23, 2024 | 2.943B |
| September 20, 2024 | 3.049B |
| September 19, 2024 | 3.156B |
| September 18, 2024 | 3.100B |
| September 17, 2024 | 3.072B |
| September 16, 2024 | 2.848B |
| September 13, 2024 | 2.854B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-83.74M
Minimum
May 19 2022
3.840B
Maximum
Nov 08 2024
1.062B
Average
831.72M
Median
Oct 19 2020
Enterprise Value Benchmarks
| Eli Lilly and Co | 739.59B |
| TG Therapeutics Inc | 5.281B |
| Regeneron Pharmaceuticals Inc | 74.00B |
| Voyager Therapeutics Inc | -48.74M |
| Krystal Biotech Inc | 4.654B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -43.64M |
| Revenue (Quarterly) | 33.25M |
| Total Expenses (Quarterly) | 77.14M |
| EPS Diluted (Quarterly) | -0.73 |
| Gross Profit Margin (Quarterly) | 88.49% |
| Profit Margin (Quarterly) | -131.2% |
| Earnings Yield | -7.34% |
| Normalized Earnings Yield | -7.530 |